Login to Your Account

Biocompatibles in $422M Deal With AstraZeneca in Diabetes

By Nuala Moran

Wednesday, December 24, 2008
LONDON - Biocompatibles International plc sealed a deal with AstraZeneca plc worth a potential €302.3 million (US$422.6 million) for a glucagon-like peptide (GLP-1) analogue for treating diabetes and obesity. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription